It is very important for manufacturers to communicate with the healthcare system and members of the medical community, such as chief freelance specialists, colleagues from the Ministry of Health, and colleagues from the regions, to receive feedback on products and the areas of dissatisfaction with medicine. If the medical community points them out to the industry, this is an additional, but very important tool for shaping the offering. If everyone works together to fine-tune the product that is needed, it will be both in demand and useful — Dmitriy Galkin, Director of Department of Pharmaceutical and Medical Industry Development, Ministry of Industry and Trade of the Russian Federation.
When we talk about more coherence in decision-making, there should not be separate registration of medicines, separate medical practices, which can only be based on one particular system, and separate registration of prices. These things should all be interlinked. This is also a tool for analysis. And that is the thing! For example, the atomization of a doctor as a source of medical practice and the rejection of statistically significant data and international best practice, which develops all over the world, can lead to completely different results in terms of pricing — Timofey Nizhegorodtsev, Deputy Head, Federal Antimonopoly Service of the Russian Federation.